MX2021000459A - Metodo para producir celulas t gamma y delta. - Google Patents
Metodo para producir celulas t gamma y delta.Info
- Publication number
- MX2021000459A MX2021000459A MX2021000459A MX2021000459A MX2021000459A MX 2021000459 A MX2021000459 A MX 2021000459A MX 2021000459 A MX2021000459 A MX 2021000459A MX 2021000459 A MX2021000459 A MX 2021000459A MX 2021000459 A MX2021000459 A MX 2021000459A
- Authority
- MX
- Mexico
- Prior art keywords
- cells
- delta
- producing gamma
- producing
- gamma
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/35—Cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
- C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/145—Thrombopoietin [TPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2321—Interleukin-21 (IL-21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/48—Regulators of apoptosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases [EC 2.]
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018133727 | 2018-07-13 | ||
| JP2019117891 | 2019-06-25 | ||
| PCT/JP2019/027697 WO2020013315A1 (ja) | 2018-07-13 | 2019-07-12 | γδT細胞の製造方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021000459A true MX2021000459A (es) | 2021-06-23 |
Family
ID=69143058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021000459A MX2021000459A (es) | 2018-07-13 | 2019-07-12 | Metodo para producir celulas t gamma y delta. |
Country Status (14)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| EP3822342A4 (en) * | 2018-07-13 | 2022-08-03 | Kyoto University | METHOD OF PRODUCTION OF GAMMA DELTA T-CELLS |
| CN109337870B (zh) | 2018-12-24 | 2020-07-03 | 广东暨德康民生物科技有限责任公司 | 人Vγ9Vδ2T细胞扩增方法与培养基 |
| JP7879804B2 (ja) * | 2019-12-06 | 2026-06-24 | フェイト セラピューティクス,インコーポレイテッド | 小化合物を使用するiPSC由来エフェクター免疫細胞の増強 |
| CN115885038A (zh) | 2020-06-17 | 2023-03-31 | 国立大学法人京都大学 | 表达嵌合抗原受体的免疫活性细胞 |
| JPWO2022059780A1 (cg-RX-API-DMAC7.html) * | 2020-09-18 | 2022-03-24 | ||
| EP4289940A4 (en) * | 2021-02-05 | 2025-02-26 | National University Corporation Kobe University | ?? T-CELLS FROM INDUCED PLURIPOTENT STEM CELLS AND PRODUCTION PROCESSES THEREFOR |
| AU2022252997A1 (en) * | 2021-04-07 | 2023-09-28 | Century Therapeutics, Inc. | Compositions and methods for generating gamma-delta t cells from induced pluripotent stem cells |
| CN113583955A (zh) * | 2021-08-24 | 2021-11-02 | 羽铂精制生物技术(成都)有限公司 | 一种因子法扩增t细胞的培养基及培养方法 |
| US20230124097A1 (en) * | 2021-10-14 | 2023-04-20 | Appia Bio, Inc. | Engineering stem cell t cells with multiple t cell receptors |
| IL312734A (en) * | 2021-11-12 | 2024-07-01 | Janssen Biotech Inc | Materials and methods for improved expansion and uses of immune cells |
| JPWO2023149555A1 (cg-RX-API-DMAC7.html) | 2022-02-04 | 2023-08-10 | ||
| PE20242341A1 (es) * | 2022-04-04 | 2024-12-12 | Gammadelta Therapeutics Ltd | Blindaje genetico novedoso |
| EP4628504A3 (en) * | 2022-04-04 | 2025-12-10 | Gammadelta Therapeutics Ltd | Cells expressing an anti-mesothelin car |
| EP4508193A4 (en) * | 2022-04-11 | 2026-04-29 | In8Bio Inc | IPSC-BASED GAMMA-DELTA T LYMPHOCYTES: COMPOSITIONS AND METHODS OF USE |
| CN118931834B (zh) * | 2024-03-07 | 2025-09-16 | 珠海善行免疫微生态产业研究院有限公司 | 一种人Vγ9Vδ2T细胞扩增培养基及其扩增培养方法 |
| WO2026096605A1 (en) * | 2024-10-31 | 2026-05-07 | Pointloma Biosciences, Inc. | Methods for activation and expansion of gamma delta t cells |
| CN119530215A (zh) * | 2024-11-27 | 2025-02-28 | 珠海医米诺赛医学检验有限公司 | 一种血液处理液及利用该处理液进行染色体核型分析的方法 |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4937190A (en) | 1987-10-15 | 1990-06-26 | Wisconsin Alumni Research Foundation | Translation enhancer |
| ES2336302T3 (es) | 2000-04-03 | 2010-04-12 | Therapure Biopharma Inc. | Produccion de celulas ttcr gamma delta. |
| US9453219B2 (en) | 2003-05-15 | 2016-09-27 | Mello Biotech Taiwan Co., Ltd. | Cosmetic designs and products using intronic RNA |
| WO2006006720A1 (ja) | 2004-07-13 | 2006-01-19 | Medinet., Co.Ltd | γδT細胞の培養方法、γδT細胞及び治療・予防剤 |
| EP2206724A1 (en) | 2005-12-13 | 2010-07-14 | Kyoto University | Nuclear reprogramming factor |
| DK3399025T3 (da) | 2007-03-23 | 2025-06-16 | Wisconsin Alumni Res Found | Omprogrammering af somatiske celler |
| EP3031916B1 (en) | 2007-06-11 | 2017-06-07 | Takara Bio Inc. | Method for expression of specific gene |
| JP2008307007A (ja) | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞 |
| WO2009032194A1 (en) | 2007-08-31 | 2009-03-12 | Whitehead Institute For Biomedical Research | Wnt pathway stimulation in reprogramming somatic cells |
| AU2008297024B2 (en) | 2007-10-31 | 2014-08-28 | Kyoto University | Nuclear reprogramming method |
| KR101532442B1 (ko) | 2007-12-10 | 2015-06-29 | 고쿠리츠 다이가쿠 호진 교토 다이가쿠 | 효율적인 핵 초기화 방법 |
| EP2242838A1 (en) | 2007-12-17 | 2010-10-27 | GliaMed, Inc. | Stem-like cells and method for reprogramming adult mammalian somatic cells |
| JP5945385B2 (ja) | 2008-01-16 | 2016-07-05 | リン、シー−ランLIN, Shi−Lung | 誘導性組換えrna因子を用いた腫瘍のない多能性胚性幹様細胞の生成 |
| EP2250252A2 (en) | 2008-02-11 | 2010-11-17 | Cambridge Enterprise Limited | Improved reprogramming of mammalian cells, and the cells obtained |
| EP2090649A1 (en) | 2008-02-13 | 2009-08-19 | Fondazione Telethon | Method for reprogramming differentiated cells |
| WO2009102983A2 (en) | 2008-02-15 | 2009-08-20 | President And Fellows Of Harvard College | Efficient induction of pluripotent stem cells using small molecule compounds |
| JP5951254B2 (ja) | 2008-03-17 | 2016-07-13 | ザ スクリプス リサーチ インスティテュート | 人工多能性幹細胞を作製するための化学的手法と遺伝的手法の組み合わせ法 |
| WO2009114949A1 (en) | 2008-03-20 | 2009-09-24 | UNIVERSITé LAVAL | Methods for deprogramming somatic cells and uses thereof |
| CN102083982A (zh) | 2008-04-07 | 2011-06-01 | 纽珀滕索有限公司 | 通过rna干扰引入复能基因而重编程细胞 |
| CA2695590C (en) | 2008-06-27 | 2018-01-09 | Kyoto University | Method of efficiently establishing induced pluripotent stem cells |
| JP4281071B1 (ja) | 2008-07-10 | 2009-06-17 | 学校法人兵庫医科大学 | Vγ9Vδ2T細胞の増殖剤、活性化Vγ9Vδ2T細胞の製造方法およびこれらの利用 |
| WO2010009015A2 (en) | 2008-07-14 | 2010-01-21 | Oklahoma Medical Research Foundation | Production of pluripotent cells through inhibition of bright/arid3a function |
| WO2010147612A1 (en) | 2009-06-18 | 2010-12-23 | Lixte Biotechnology, Inc. | Methods of modulating cell regulation by inhibiting p53 |
| WO2010033920A2 (en) | 2008-09-19 | 2010-03-25 | Whitehead Institute For Biomedical Research | Compositions and methods for enhancing cell reprogramming |
| WO2010033906A2 (en) | 2008-09-19 | 2010-03-25 | President And Fellows Of Harvard College | Efficient induction of pluripotent stem cells using small molecule compounds |
| WO2010042800A1 (en) | 2008-10-10 | 2010-04-15 | Nevada Cancer Institute | Methods of reprogramming somatic cells and methods of use for such cells |
| EP2342333A4 (en) | 2008-10-30 | 2013-05-08 | Univ Kyoto | Method for producing induced pluripotent stem cells |
| WO2010056831A2 (en) | 2008-11-12 | 2010-05-20 | Nupotential, Inc. | Reprogramming a cell by inducing a pluripotent gene through use of an hdac modulator |
| EP2376626A4 (en) | 2008-12-13 | 2012-10-17 | Dna Microarray | MICRO-ENVIRONMENTAL NICHE ASSAY FOR SCREENING OF INDUCED PLURIPOTENT STEM CELLS (CIPS) |
| CA2753845C (en) | 2009-02-27 | 2019-10-29 | Kyoto University | Nuclear reprogramming substance comprising glis1 |
| US20120122212A1 (en) | 2009-03-06 | 2012-05-17 | Marica Grskovic | Tgf-beta pathway inhibitors for enhancement of cellular reprogramming of human cells |
| US20120076762A1 (en) | 2009-03-25 | 2012-03-29 | The Salk Institute For Biological Studies | Induced pluripotent stem cell generation using two factors and p53 inactivation |
| WO2010111409A2 (en) | 2009-03-25 | 2010-09-30 | The Salk Institute For Biological Studies | Pluripotent stem cells |
| US8852940B2 (en) | 2009-04-01 | 2014-10-07 | The Regents Of The University Of California | Embryonic stem cell specific microRNAs promote induced pluripotency |
| EP2421956A4 (en) | 2009-04-24 | 2013-10-02 | Whitehead Biomedical Inst | COMPOSITIONS AND METHODS FOR OBTAINING OR CULTURING PLURIPOTENTER CELLS |
| CN105925535A (zh) | 2009-06-05 | 2016-09-07 | 细胞动力国际有限公司 | 重编程t细胞和造血细胞的方法 |
| WO2010147395A2 (en) | 2009-06-16 | 2010-12-23 | Korea Research Institute Of Bioscience And Biotechnology | Medium composition comprising neuropeptide y for the generation, maintenance, prologned undifferentiated growth of pluripotent stem cells and method of culturing pluripotent stem cell using the same |
| US9206394B2 (en) * | 2010-02-03 | 2015-12-08 | The University Of Tokyo | Method for reconstructing immune function using pluripotent stem cells |
| US9834754B2 (en) | 2011-11-21 | 2017-12-05 | University Health Network | Populations of hematopoietic progenitors and methods of enriching stem cells therefor |
| EP3789487A1 (en) * | 2013-04-03 | 2021-03-10 | Memorial Sloan Kettering Cancer Center | Effective generation of tumor-targeted t-cells derived from pluripotent stem cells |
| AU2015290554A1 (en) * | 2014-07-18 | 2017-03-09 | Kyoto University | Method for inducing T cells for cell-based immunotherapy from pluripotent stem cells |
| EP3170895A4 (en) | 2014-07-18 | 2018-07-11 | Kawamoto, Hiroshi | Production method for pluripotent stem cells having antigen-specific t cell receptor gene |
| CA2964785A1 (en) * | 2014-11-05 | 2016-05-12 | Board Of Regents, The University Of Texas System | Gene modified immune effector cells and engineered cells for expansion of immune effector cells |
| US10660915B2 (en) * | 2014-11-13 | 2020-05-26 | Kyoto University | Method for induction of T cells from pluripotent stem cells |
| GB201421716D0 (en) | 2014-12-05 | 2015-01-21 | King S College London | Cell expansion procedure |
| US12005078B2 (en) * | 2015-09-03 | 2024-06-11 | The Uab Research Foundation | Genetically engineered drug resistant T cells and methods of using the same |
| WO2017065288A1 (ja) * | 2015-10-15 | 2017-04-20 | 国立大学法人京都大学 | 多能性幹細胞からcd4陽性t細胞を製造する方法 |
| KR102929174B1 (ko) | 2015-10-30 | 2026-02-20 | 더 리전츠 오브 더 유니버시티 오브 캘리포니아 | 줄기세포로부터 t-세포를 생산하는 방법 및 상기 t-세포를 이용한 면역치료 방법 |
| LT3444334T (lt) * | 2016-04-15 | 2021-12-10 | Kyoto University | Antigenui specifinių cd8 teigiamų t ląstelių indikavimo būdas |
| WO2017221975A1 (ja) | 2016-06-23 | 2017-12-28 | 国立大学法人京都大学 | Cd4cd8両陽性t細胞の製造方法 |
| EP3572502B1 (en) | 2017-01-20 | 2023-01-11 | Kyoto University | Method for producing cd8alpha +beta + cytotoxic t cells |
| JP7224021B2 (ja) | 2017-02-03 | 2023-02-17 | 国立大学法人神戸大学 | 人工多能性幹細胞の作製方法 |
| WO2018147801A1 (en) * | 2017-02-07 | 2018-08-16 | Agency For Science, Technology And Research | Methods and kits for generating mimetic innate immune cells from pluripotent stem cells |
| JP2018133727A (ja) | 2017-02-16 | 2018-08-23 | 富士通株式会社 | 無線通信システム、無線通信装置、及びビームパターン決定方法 |
| JP7171055B2 (ja) * | 2017-03-14 | 2022-11-15 | 国立大学法人京都大学 | 多能性幹細胞からヘルパーt細胞を製造する方法 |
| JP7109916B2 (ja) | 2017-12-27 | 2022-08-01 | 株式会社ディスコ | 分割装置 |
| EP3822342A4 (en) | 2018-07-13 | 2022-08-03 | Kyoto University | METHOD OF PRODUCTION OF GAMMA DELTA T-CELLS |
| WO2020027094A1 (ja) * | 2018-07-31 | 2020-02-06 | サイアス株式会社 | iPS細胞を介して再生T細胞集団を製造する方法 |
| AR120348A1 (es) * | 2019-11-01 | 2022-02-09 | Univ Kyoto | Método para producir células t |
| BR112022009181A2 (pt) * | 2019-11-25 | 2022-07-26 | Univ Kyoto | Sistema para prover um produto de célula t, métodos para produzir um produto de célula t, para construir um banco celular e uma coleção de produto de célula t e para prover um produto de célula t, banco celular, coleções de banco celular e de produto de célula t, e, produto de célula t |
| JPWO2022059780A1 (cg-RX-API-DMAC7.html) * | 2020-09-18 | 2022-03-24 | ||
| EP4219707A4 (en) * | 2020-09-24 | 2024-11-13 | Kyoto University | METHOD FOR PRODUCING AN EFFECTOR CELL WITH DESIRED SPECIFICITY |
| EP4273234A4 (en) * | 2021-01-04 | 2025-04-23 | Thyas Co. Ltd. | Method for producing a regenerated T cell via an IPS cell |
-
2019
- 2019-07-12 EP EP19833471.6A patent/EP3822342A4/en active Pending
- 2019-07-12 WO PCT/JP2019/027697 patent/WO2020013315A1/ja not_active Ceased
- 2019-07-12 TW TW114143369A patent/TW202609051A/zh unknown
- 2019-07-12 AU AU2019302207A patent/AU2019302207B2/en active Active
- 2019-07-12 SG SG11202100260QA patent/SG11202100260QA/en unknown
- 2019-07-12 TW TW108124699A patent/TW202020145A/zh unknown
- 2019-07-12 KR KR1020217002142A patent/KR102975736B1/ko active Active
- 2019-07-12 CN CN201980050138.3A patent/CN112513256A/zh active Pending
- 2019-07-12 JP JP2020530276A patent/JP7479635B2/ja active Active
- 2019-07-12 BR BR112021000437-8A patent/BR112021000437A2/pt unknown
- 2019-07-12 CA CA3106089A patent/CA3106089A1/en active Pending
- 2019-07-12 MX MX2021000459A patent/MX2021000459A/es unknown
- 2019-07-12 US US17/259,736 patent/US12391739B2/en active Active
-
2021
- 2021-01-10 IL IL280041A patent/IL280041A/en unknown
- 2021-01-29 CO CONC2021/0001064A patent/CO2021001064A2/es unknown
-
2024
- 2024-04-16 JP JP2024065962A patent/JP7817708B2/ja active Active
-
2025
- 2025-07-11 US US19/266,860 patent/US20260152542A1/en active Pending
- 2025-07-11 US US19/266,773 patent/US20260152541A1/en active Pending
- 2025-07-11 US US19/266,956 patent/US20250333470A1/en active Pending
- 2025-10-29 JP JP2025182692A patent/JP2026021431A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL280041A (en) | 2021-03-01 |
| US20260152542A1 (en) | 2026-06-04 |
| SG11202100260QA (en) | 2021-02-25 |
| US20210130777A1 (en) | 2021-05-06 |
| US20260152541A1 (en) | 2026-06-04 |
| TW202020145A (zh) | 2020-06-01 |
| AU2019302207A1 (en) | 2021-03-04 |
| US12391739B2 (en) | 2025-08-19 |
| WO2020013315A1 (ja) | 2020-01-16 |
| JP2024096899A (ja) | 2024-07-17 |
| CA3106089A1 (en) | 2020-01-16 |
| US20250333470A1 (en) | 2025-10-30 |
| JP7479635B2 (ja) | 2024-05-09 |
| EP3822342A1 (en) | 2021-05-19 |
| CO2021001064A2 (es) | 2021-02-08 |
| KR20210030373A (ko) | 2021-03-17 |
| AU2019302207B2 (en) | 2025-11-20 |
| BR112021000437A2 (pt) | 2021-04-06 |
| EP3822342A4 (en) | 2022-08-03 |
| JPWO2020013315A1 (ja) | 2021-08-02 |
| JP2026021431A (ja) | 2026-02-10 |
| JP7817708B2 (ja) | 2026-02-19 |
| KR102975736B1 (ko) | 2026-06-11 |
| CN112513256A (zh) | 2021-03-16 |
| TW202609051A (zh) | 2026-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021006235A (es) | Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos. | |
| MX2019007020A (es) | Anticuerpos il-11. | |
| PH12019502294A1 (en) | Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap | |
| MX2019007021A (es) | Anticuerpos il-11ra. | |
| MX2021006564A (es) | Sistemas activos dinamicos acromosomicos. | |
| CO2021001064A2 (es) | Método para la producción de las células t gamma delta | |
| MX2022015555A (es) | Metodos para preparar celulas t para terapia de celulas t. | |
| IL286776A (en) | Compositions and methods for preparing t cell compositions and uses thereof | |
| CR20180525A (es) | Producción de ácido ribonucleico libre de células | |
| IL249828A0 (en) | Limbal stem cells of cultured mammals, methods of their creation and uses thereof | |
| IL283074A (en) | Dendritic cell generating apparatus and method | |
| MX385749B (es) | Composiciones que comprenden una caseína y métodos para producir las mismas. | |
| DK3607055T3 (da) | Sammensætninger til omprogrammering af celler til dendritiske celler eller antigenpræsenterende celler, fremgangsmåder og anvendelser deraf | |
| BR112017018885A2 (pt) | método de cultura celular para células-tronco mesenquimais | |
| AU2016250905A8 (en) | Generation of muscle-lineage cells from stem cells | |
| GB2548059A (en) | Induced hepatocytes and uses thereof | |
| MX2020003515A (es) | Laminados elasticos con elasticos curvos y metodos para la fabricacion. | |
| PH12020551292A1 (en) | Moscato wine replicas produced from individual components | |
| ES2721309T3 (es) | Composición para preparar tagatosa y método para preparar tagatosa a partir de fructosa | |
| MX2019011758A (es) | Composicion para producir tagatosa y procedimiento de produccion de tagatosa usando la misma. | |
| TW201612308A (en) | Collector architecture layout design | |
| WO2016164896A3 (en) | Modulation of smn expression | |
| MX2020012893A (es) | Formulaciones de proteinas. | |
| MX2019015868A (es) | Nueva psicosa-6-fosfato fosfatasa, composición para producir psicosa que incluye dicha enzima, método para producir psicosa usando dicha enzima. | |
| EA201791233A1 (ru) | Материал стволовых клеток и способ его получения |